Cancer Blog
Opportunities and Perspectives on the Design and Synthesis of PROTAC® Degraders
Development of a KRAS-Targeting PROTAC
In this question-and-answer session, Michael Bond (Yale University) talks to our Senior Product Specialist, Alex Moloney PhD, about the development of LC 2, a KRAS G12C-targeting PROTAC® which is now available from Tocris.
dTAG - A Protein Degradation Platform for Target Validation
Targeting the Immune System in Cancer with Small Molecules
RAS - The Undruggable Target
Long-termed the “undruggable target”, RAS has recently recaptured the attention of cancer researchers. A new understanding of this target has once again reignited hopes of modulating it to tackle some of the most lethal cancers.